Veritas Pharma Inc
Indigenous Bloom Hemp Corp. focuses on the production of hemp products. It sells hemp biomass and flowers, as well as phytocannabinoid rich extracts derived from hemp biomass. The company is headquartered in Kelowna, Canada.
Veritas Pharma Inc (VRTHF) - Net Assets
Latest net assets as of February 2023: $-2.76 Million USD
Based on the latest financial reports, Veritas Pharma Inc (VRTHF) has net assets worth $-2.76 Million USD as of February 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($560.94K) and total liabilities ($3.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.76 Million |
| % of Total Assets | -492.47% |
| Annual Growth Rate | N/A |
| 5-Year Change | -168.14% |
| 10-Year Change | N/A |
| Growth Volatility | 365.99 |
Veritas Pharma Inc - Net Assets Trend (2014–2022)
This chart illustrates how Veritas Pharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Veritas Pharma Inc (2014–2022)
The table below shows the annual net assets of Veritas Pharma Inc from 2014 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-05-31 | $-2.45 Million | -89.24% |
| 2021-05-31 | $-1.29 Million | -46.83% |
| 2020-05-31 | $-881.47K | -157.11% |
| 2019-05-31 | $-342.83K | -109.54% |
| 2018-05-31 | $3.59 Million | +37.67% |
| 2017-05-31 | $2.61 Million | +534.27% |
| 2016-05-31 | $411.68K | +45.62% |
| 2015-05-31 | $282.70K | +862.97% |
| 2014-05-31 | $29.36K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Veritas Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 305559200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (May 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $523.72K | % |
| Other Comprehensive Income | $126.62K | % |
| Total Equity | $-2.45 Million | 100.00% |
Veritas Pharma Inc Competitors by Market Cap
The table below lists competitors of Veritas Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hyflux Ltd
PINK:HYFXF
|
$78.52K |
|
Darwin AG
XETRA:7V0
|
$78.60K |
|
Discoverie Group PLC
LSE:DSCV
|
$78.70K |
|
PETR3F
SA:PETR3F
|
$78.71K |
|
BURFORD CAP -NPV-
BE:9BF
|
$78.27K |
|
CLP HLDGS
MU:CLP
|
$78.16K |
|
Invictus Financial Inc
PINK:IVFZF
|
$78.12K |
|
Lindbergh S.p.A.
F:D8M
|
$78.12K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Veritas Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -1,294,290 to -2,449,377, a change of -1,155,087.
- Net loss of 2,289,971 reduced equity.
- Other comprehensive income decreased equity by 2,001,592.
- Other factors increased equity by 3,136,476.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.29 Million | -93.49% |
| Other Comprehensive Income | $-2.00 Million | -81.72% |
| Other Changes | $3.14 Million | +128.05% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Veritas Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-05-31 | $0.29 | $0.00 | x |
| 2016-05-31 | $0.40 | $0.00 | x |
| 2017-05-31 | $1.60 | $0.00 | x |
| 2018-05-31 | $1.53 | $0.00 | x |
| 2019-05-31 | $-0.08 | $0.00 | x |
| 2020-05-31 | $-0.14 | $0.00 | x |
| 2021-05-31 | $-0.16 | $0.00 | x |
| 2022-05-31 | $-0.03 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Veritas Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-179.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -762.05% | 0.00% | 0.00x | 1.31x | $-226.65K |
| 2015 | -257.79% | 0.00% | 0.00x | 1.77x | $-757.05K |
| 2016 | -203.26% | 0.00% | 0.00x | 1.20x | $-877.94K |
| 2017 | -94.60% | 0.00% | 0.00x | 1.22x | $-2.37 Million |
| 2018 | -300.82% | 0.00% | 0.00x | 1.05x | $-11.17 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.85 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.69 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-472.85K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.05 Million |
Industry Comparison
This section compares Veritas Pharma Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Veritas Pharma Inc (VRTHF) | $-2.76 Million | -762.05% | N/A | $78.48K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |